Rocket Pharmaceuticals, Inc. Available-for-sale Securities, Gross Unrealized Gain
Rocket Pharmaceuticals, Inc. (RCKT) reported Available-for-sale Securities, Gross Unrealized Gain of $10.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains · last filed 2018-05-11
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized gain for the quarter ending 2018-03-31 was $10.00K.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized gain for the quarter ending 2016-12-31 was -$7.00K.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized gain for the quarter ending 2016-09-30 was -$9.00K.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized gain for the quarter ending 2016-06-30 was $14.00K.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized gain for fiscal 2016 was $1.00K.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized gain for fiscal 2015 was $0.00.
| Period end | Available-for-sale Securities, Gross Unrealized Gain 3 month | Available-for-sale Securities, Gross Unrealized Gain 6 month | Available-for-sale Securities, Gross Unrealized Gain 9 month | Available-for-sale Securities, Gross Unrealized Gain 12 month |
|---|---|---|---|---|
| 2018-03-31 | $10.00K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$16.00K derived: sum of 2 quarters · filed 2018-03-07 | -$2.00K derived: sum of 3 quarters · filed 2018-03-07 | $1.00K 10-K · filed 2018-03-07 |
| 2016-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $5.00K derived: sum of 2 quarters · filed 2016-11-09 | $8.00K 10-Q · filed 2016-11-09 | $7.00K derived: sum of 4 quarters · filed 2016-11-09 |
| 2016-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $17.00K 10-Q · filed 2016-08-10 | $16.00K derived: sum of 3 quarters · filed 2016-08-10 | |
| 2016-03-31 | $3.00K 10-Q · filed 2016-05-11 | $2.00K derived: sum of 2 quarters · filed 2016-05-11 | ||
| 2015-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $0.00 10-K · filed 2016-03-23 | ||
| 2015-09-30 | $1.00K 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |